Skip to main content
    R

    Rallybio Corp (RLYB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.29
    -0.13 (-0.88%)

    Market Cap: $88.03M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Rallybio Corp (RLYB) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Rallybio (RLYB) trades at 201.3x sales and 0.9x book value. Its P/B of 0.9x is below its 5-year median of 1.0x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales201.3x
    Price to book0.9x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B0.9x1.0xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 3 of the 5 year ends shown that have a P/S, its P/S ranged from 35.3x in 2025 to 426.0x in 2023.

    Year endPriceP/SP/B
    2025$5.4935.3x0.5x
    2024$7.6867.0x0.7x
    2023$19.12426.0x0.9x
    2022$52.56N/A1.4x
    2021$76.32N/A1.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About RLYB

    What is RLYB's price to sales ratio?

    Rallybio has a price to sales ratio of 201.3x.